All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 LDH > ULN LDH ≤ULN PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% stage M0/M1A/M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - L1 - all population, nivolumab alone vs. ..., meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.54 [1.25; 1.89]
1.54 [1.25 ; 1.89 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 630 NA not evaluable deaths (OS) (extension)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.20 [0.97; 1.49]
1.20 [0.97 ; 1.49 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 630 NA not evaluable PFS (extension)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.27 [1.03; 1.55]
1.27 [1.03 ; 1.55 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 630 NA not evaluable progression or deaths (PFS)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.35 [1.09; 1.67]
1.35 [1.09 ; 1.67 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 630 NA not evaluable objective responses (ORR)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.57 [0.42; 0.78]
0.57 [0.42 ; 0.78 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 630 NA not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.17 [0.12; 0.24]
0.17 [0.12 ; 0.24 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 630 NA not evaluable TRAE (any grade)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.28 [0.15; 0.53]
0.28 [0.15 ; 0.53 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.21 [0.15; 0.29]
0.21 [0.15 ; 0.29 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.02 ; 50.56 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.21 [0.14; 0.31]
0.21 [0.14 ; 0.31 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.20 [0.12; 0.32]
0.20 [0.12 ; 0.32 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
0.50 [0.02 ; 14.93 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.07; 1.64]
0.33 [0.07 ; 1.64 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.04; 5.52]
0.50 [0.04 ; 5.52 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.06; 16.06]
1.00 [0.06 ; 16.06 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.11 [0.03; 0.36]
0.11 [0.03 ; 0.36 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 4.02 [0.18; 89.49]
4.02 [0.18 ; 89.49 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.12 [0.01; 2.35]
0.12 [0.01 ; 2.35 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.29 [0.13; 0.62]
0.29 [0.13 ; 0.62 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.02 ; 50.56 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.03; 3.20]
0.33 [0.03 ; 3.20 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.22 [0.06; 0.79]
0.22 [0.06 ; 0.79 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.25 [0.01; 5.54]
0.25 [0.01 ; 5.54 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.10 [0.01; 1.81]
0.10 [0.01 ; 1.81 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.17 [0.01; 3.31]
0.17 [0.01 ; 3.31 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.20 [0.02; 1.70]
0.20 [0.02 ; 1.70 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
0.50 [0.02 ; 14.93 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.15 [0.04; 0.51]
0.15 [0.04 ; 0.51 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.14 [0.05; 0.40]
0.14 [0.05 ; 0.40 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.38 [0.20; 0.73]
0.38 [0.20 ; 0.73 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.07; 1.64]
0.33 [0.07 ; 1.64 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.06; 16.06]
1.00 [0.06 ; 16.06 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.07 [0.00; 1.24]
0.07 [0.00 ; 1.24 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.33 [0.03; 3.20]
0.33 [0.03 ; 3.20 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.02 ; 50.56 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.16 [0.02; 1.37]
0.16 [0.02 ; 1.37 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.25 [0.01; 5.54]
0.25 [0.01 ; 5.54 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.10 [0.01; 0.76]
0.10 [0.01 ; 0.76 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.50 [0.02; 14.93]
0.50 [0.02 ; 14.93 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 2.00 [0.07; 59.93]
2.00 [0.07 ; 59.93 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 0.14 [0.02; 1.15]
0.14 [0.02 ; 1.15 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1.00 [0.02; 50.56]
1.00 [0.02 ; 50.56 ] CheckMate 067 (NI vs N) EXPLORATORY, 2015 (REV) 1 0% 626 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-06 22:42 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 68
- treatments: 360,719,721,720
